Actively Recruiting
Study of BG-75202 Alone and with Other Agents to Assess Safety and Early Effects in Adults with Myeloid Malignancies
Led by BeOne Medicines · Updated on 2026-09-28
118
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BG-75202, a KAT6AB inhibitor, alone and combined with other agents to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and early effectiveness in adults with myeloid malignancies. This Phase 1a1b trial focuses on patients with relapsed or refractory myeloid cancers who have received prior treatments. The study aims to identify appropriate dosing and evaluate treatment responses according to established criteria. Participants will receive BG-75202 as monotherapy or in combination with a hypomethylation agent HMA. The study follows sequential cohorts with increasing doses to determine safe and effective doses. BG-75202 is given orally, while the HMA is administered intravenously or subcutaneously. The trial includes dose escalation and dose optimization phases to find the recommended doses for expansion and further study. Throughout the trial, participants will be closely monitored for adverse events and treatment responses for up to 18 months. Researchers will collect pharmacokinetic data, including drug concentration in plasma over time, and measure clinical outcomes such as complete remission rates and survival. Safety assessments continue for 30 days after the last dose or until new anticancer therapy starts. Participants health and blood work will be regularly evaluated to track the effects of the study drugs.
CONDITIONS
Brief Title
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here